SLC22A2 and breast cancer: In the present study, we sought to determine the impact of CIM on the anticancer effects of CIS and quantitatively characterize their nature of interactions in two cancer cells, OCT2-negative HCC cell line, Huh7, and OCT2-positive breast cancer cell line MDA-MB-468.